No Data
No Data
Promising Developments in BioNTech's Oncology Pipeline Drive Buy Rating
BioNTech Analyst Ratings
Tempus Stock Declines Despite Q3 Earnings & Revenues Beat Estimates
TD Cowen Maintains BioNTech(BNTX.US) With Hold Rating, Maintains Target Price $122
Oppenheimer Maintains BioNTech(BNTX.US) With Hold Rating
Evercore Maintains BioNTech(BNTX.US) With Hold Rating, Raises Target Price to $110
No Data
No Data